Skip directly to search Skip directly to A to Z list Skip directly to navigation Skip directly to page options Skip directly to site content

CDC Science Clips
COVID-10 GPH

Last data update: Aug 15, 2025. (Total: 49733 publications since 2009)
(Author names in bold with hyperlink are CDC authors)
Filtered By:
Order By:
Records 1-3 (of 3 Records)
Query Trace: Simons-Petrusa B[original query]
Successful Transition to Whole-Genome Sequencing and Bioinformatics to Identify Invasive Streptococcus spp. Drug Resistance, Alaska, USA
Miernyk KM , Chochua S , Metcalf B , Reasonover A , Simons-Petrusa B .
Emerg Infect Dis 2025 31 (13) 103-108 type type

The Centers for Disease Control and Prevention's Arctic Investigations Program evaluated whole-genome sequencing (WGS) workflows and bioinformatics pipelines developed by the Centers' Streptococcus Laboratory. We compared WGS-based antimicrobial drug resistance predictions with phenotypic testing for group B (n = 130) and group A (n = 217) Streptococcus and Streptococcus pneumoniae (n = 293). Isolates were collected in Alaska during January 2019-February 2021. We also included a historical phenotypically nonsusceptible subset. Concordances between phenotypic testing and WGS predictions were 99.9% (895/896) for group B Streptococcus, 100% (1,298/1,298) for group A Streptococcus, and 99.98% (3,516/3,517) for S. pneumoniae. Common resistance determinants were ermTR, ermB, and mef for macrolides, tetM for tetracyclines, and gyrA and parC for levofloxacin. S. pneumoniae trimethoprim/sulfamethoxazole nonsusceptibility was associated with folP gene insertions and folA mutations. In 2022, the Arctic Investigations Program transitioned Streptococcus spp. workflows to WGS, enabling more rapid monitoring and prevention of invasive disease.
Impact of Pneumococcal Conjugate Vaccines on Otitis Media among American Indian/Alaska Native Children in the Southwest United States
Sergent VM , Sutcliffe CG , Yazzie D , Brasinikas G , Brown LB , Christensen L , Clichee D , Damon S , Dixon SL , Grant LR , Harker-Jones M , McAuley JB , Montanez P , Parker Riley D , Reasonover A , Rice A , Romancito E , Salabye C , Simons-Petrusa B , Tenequer VL , Thompson P , Tsingine M , Tso C , Weatherholtz RC , Hammitt LL .
J Pediatric Infect Dis Soc 2025 14 (3)

We assessed the impact of pneumococcal conjugate vaccines on pneumococcal otitis media (OM) among children living in Navajo and White Mountain Apache Tribal lands. During the PCV7 era (2000-2009), the proportion of vaccine-type OM declined. However, vaccine-type OM (predominantly 3, 19A, and 19F) persisted in the PCV13 era (2010-2019).
Impact of the COVID-19 pandemic on invasive pneumococcal disease in American Indian communities in the Southwest US
Sutcliffe CG , Littlepage S , Yazzie D , Brasinikas G , Christensen L , Damon S , Denny E , Dixon SL , Grant LR , Harker-Jones M , McAuley J , Montanez P , Parker D , Reasonover A , Rice A , Roessler K , Romancito E , Salabye C , Sergent VM , Simons-Petrusa B , Tenequer V , Thompson P , Tsingine M , Weatherholtz RC , Hammitt LL .
J Med Microbiol 2025 74 (3) type type

American Indian (AI) communities in the Southwest have a high burden of invasive pneumococcal disease (IPD) and COVID-19. Through laboratory-based surveillance, the impact of the pandemic on IPD incidence and serotype distribution was evaluated in two AI communities. IPD rates were lower during the pandemic (21.8 vs. 39.0/100 000 pre-pandemic). Rates increased in 2021 compared to 2020 but not to pre-pandemic levels. Cases with SARS-CoV-2 co-infection had a higher case fatality rate (45.2% vs. 17.6% without co-infection). No significant change in serotype distribution was observed. Continued surveillance in these communities is critical to understand the changing IPD burden as the pandemic evolves.
TOP